Published in J Virol on August 01, 1988
N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J Virol (1991) 3.55
Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol (1990) 3.46
Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol (1993) 3.07
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Scrapie prion proteins accumulate in the cytoplasm of persistently infected cultured cells. J Cell Biol (1990) 2.42
Cultured cell sublines highly susceptible to prion infection. J Virol (2000) 2.38
Prion strain discrimination in cell culture: the cell panel assay. Proc Natl Acad Sci U S A (2007) 2.30
Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol (2000) 2.15
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
The sequential development of abnormal prion protein accumulation in mice with Creutzfeldt-Jakob disease. Am J Pathol (1992) 1.66
Congo red inhibition of scrapie agent replication. J Virol (1993) 1.60
Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathway. Mol Cell Proteomics (2009) 1.52
Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. EMBO J (2001) 1.50
Overexpression of nonconvertible PrPc delta114-121 in scrapie-infected mouse neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc) accumulation. J Virol (1998) 1.49
Cellular biology of prion diseases. Clin Microbiol Rev (1999) 1.48
A bovine cell line that can be infected by natural sheep scrapie prions. PLoS One (2015) 1.44
Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol (2007) 1.26
Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cells. J Virol (1990) 1.24
Cultured peripheral neuroglial cells are highly permissive to sheep prion infection. J Virol (2004) 1.19
Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence. J Virol (1999) 1.16
Cells expressing anchorless prion protein are resistant to scrapie infection. J Virol (2009) 1.07
Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol (2004) 1.07
Two mutant prion proteins expressed in cultured cells acquire biochemical properties reminiscent of the scrapie isoform. Proc Natl Acad Sci U S A (1996) 1.01
Efficient conversion of normal prion protein (PrP) by abnormal hamster PrP is determined by homology at amino acid residue 155. J Virol (2001) 1.00
Protease sensitivity and nuclease resistance of the scrapie agent propagated in vitro in neuroblastoma cells. J Virol (1991) 1.00
Deletion of beta-strand and alpha-helix secondary structure in normal prion protein inhibits formation of its protease-resistant isoform. J Virol (2001) 0.98
Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches. PLoS One (2014) 0.88
Infectious prions accumulate to high levels in non proliferative C2C12 myotubes. PLoS Pathog (2013) 0.86
The standard scrapie cell assay: development, utility and prospects. Viruses (2015) 0.86
Cyclic tetrapyrrole sulfonation, metals, and oligomerization in antiprion activity. Antimicrob Agents Chemother (2007) 0.83
Aggregation of cellular prion protein is initiated by proximity-induced dimerization. J Neurochem (2007) 0.82
Chelating compound, chrysoidine, is more effective in both antiprion activity and brain endothelial permeability than quinacrine. Cell Mol Neurobiol (2007) 0.81
A Single Subcutaneous Injection of Cellulose Ethers Administered Long before Infection Confers Sustained Protection against Prion Diseases in Rodents. PLoS Pathog (2016) 0.78
A Neuronal Culture System to Detect Prion Synaptotoxicity. PLoS Pathog (2016) 0.76
Prions Ex Vivo: What Cell Culture Models Tell Us about Infectious Proteins. Int J Cell Biol (2013) 0.76
Identification of Anti-prion Compounds using a Novel Cellular Assay. J Biol Chem (2016) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Novel proteinaceous infectious particles cause scrapie. Science (1982) 24.09
Scrapie prions aggregate to form amyloid-like birefringent rods. Cell (1983) 7.92
Identification of a protein that purifies with the scrapie prion. Science (1982) 7.00
A protease-resistant protein is a structural component of the scrapie prion. Cell (1983) 6.72
The use of Tween 20 as a blocking agent in the immunological detection of proteins transferred to nitrocellulose membranes. J Immunol Methods (1982) 6.36
Abnormal fibrils from scrapie-infected brain. Acta Neuropathol (1981) 5.35
Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci U S A (1986) 4.38
Scrapie-infected murine neuroblastoma cells produce protease-resistant prion proteins. J Virol (1988) 3.37
Scrapie infectivity, fibrils and low molecular weight protein. Nature (1984) 3.18
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Molecular properties, partial purification, and assay by incubation period measurements of the hamster scrapie agent. Biochemistry (1980) 2.27
Scrapie-associated fibrils in Creutzfeldt-Jakob disease. Nature (1984) 2.11
Immunological comparison of scrapie-associated fibrils isolated from animals infected with four different scrapie strains. J Virol (1986) 1.95
In vitro replication of scrapie agent in a neuronal model: infection of PC12 cells. J Gen Virol (1984) 1.80
Detection of scrapie-associated fibril (SAF) proteins using anti-SAF antibody in non-purified tissue preparations. J Gen Virol (1986) 1.67
Purified scrapie prions resist inactivation by UV irradiation. J Virol (1987) 1.43
Scrapie infectious agent is virus-like in size and susceptibility to inactivation. Nature (1984) 1.28
Evidence for the multiplication of scrapie agent in cell culture. Nature (1970) 1.23
Immuno-gold localization of prion filaments in scrapie-infected hamster brains. Lab Invest (1987) 1.22
Scrapie: concept of a virus-induced amyloidosis of the brain. EMBO J (1985) 1.11
Partial copurification of scrapie-associated fibrils and scrapie infectivity. Intervirology (1986) 1.10
[Trials of in vitro propagation of the scrapie agent in mouse nerve cells]. C R Seances Acad Sci III (1981) 1.09
Search for a scrapie-specific nucleic acid: a progress report. Ciba Found Symp (1988) 0.99
Inactivation of the scrapie agent by ultraviolet irradiation in the presence of chlorpromazine. J Gen Virol (1985) 0.99
Attempts to establish cell cultures infected with the viruses of subacute spongiform encephalopathies. Proc Soc Exp Biol Med (1980) 0.91
In vitro studies with the scrapie agent. Acta Virol (1985) 0.81
The sequence of the human genome. Science (2001) 101.55
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Cell-free formation of protease-resistant prion protein. Nature (1994) 6.07
Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. Biochemistry (1991) 5.53
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 4.51
Affinity labeling of a phosphorylcholine binding mouse myeloma protein. Biochemistry (1972) 4.26
Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature (1995) 4.22
Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. Virology (1983) 4.16
Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. Neurology (2001) 4.10
Gender differences in alcohol consumption and adverse drinking consequences: cross-cultural patterns. Addiction (2000) 3.85
Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology (1981) 3.61
N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J Virol (1991) 3.55
Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop. J Virol (1997) 3.44
Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature (1985) 3.38
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol (1996) 3.21
Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex. J Exp Med (1974) 2.89
Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature (1997) 2.80
Hemolytic anemia and erythroleukemia, two distinct pathogenic effects of Friend MuLV: mapping of the effects to different regions of the viral genome. Cell (1986) 2.69
p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods (1997) 2.65
Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A (1995) 2.58
Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology (1995) 2.55
Characterization of scrapie infection in mouse neuroblastoma cells. J Gen Virol (1987) 2.54
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J Virol (1994) 2.51
Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription. EMBO J (2000) 2.48
Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses. Virology (1985) 2.44
Evidence of a molecular barrier limiting susceptibility of humans, cattle and sheep to chronic wasting disease. EMBO J (2000) 2.42
Prion protein and the transmissible spongiform encephalopathies. Trends Cell Biol (1997) 2.39
Scrapie infectivity found in resistant species. Nature (1998) 2.28
Immunity to retroviral infection: the Friend virus model. Proc Natl Acad Sci U S A (1997) 2.28
Demented and nondemented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol (1994) 2.21
Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol (2000) 2.15
Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol (1989) 2.08
An adherent dressing for aplasia cutis congenita. Br J Plast Surg (2005) 2.07
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science (1986) 2.06
Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and western blotting. J Virol Methods (1991) 2.01
Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J (2001) 1.95
Aleutian disease of mink: the antibody response of sapphire and pastel mink to Aleutian disease virus. J Immunol (1975) 1.95
Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex. Proc Natl Acad Sci U S A (1979) 1.95
Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol (2000) 1.93
Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A (1986) 1.92
Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity. J Exp Med (1976) 1.90
A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells. J Virol (1995) 1.87
Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation (1996) 1.86
Heterologous PrP molecules interfere with accumulation of protease-resistant PrP in scrapie-infected murine neuroblastoma cells. J Virol (1994) 1.85
Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A (1998) 1.80
Mutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine. J Virol (1991) 1.79
Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79
The chemistry of scrapie infection: implications of the 'ice 9' metaphor. Chem Biol (1995) 1.76
Bias against the null hypothesis: the reproductive hazards of cocaine. Lancet (1989) 1.74
Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A (2000) 1.73
Steps towards constructing a global comparative risk analysis for alcohol consumption: determining indicators and empirical weights for patterns of drinking, deciding about theoretical minimum, and dealing with different consequences. Eur Addict Res (2001) 1.73
Essentialist beliefs about social categories. Br J Soc Psychol (2000) 1.71
Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71
Strains of [PSI(+)] are distinguished by their efficiencies of prion-mediated conformational conversion. EMBO J (2001) 1.70
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA (1999) 1.70
Studies on the role of the host immune response in recovery from Friend virus leukemia. I. Antiviral and antileukemia cell antibodies. J Exp Med (1976) 1.69
Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol (1996) 1.68
Rfv-1 and Rfv-2, two H-2-associated genes that influence recovery from Friend leukemia virus-induced splenomegaly. J Immunol (1978) 1.66
The ultrastructure of normal and pathological IgM immunoglobulins. J Exp Med (1968) 1.64
Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J (1999) 1.64
Social networks as predictors of ischemic heart disease, cancer, stroke and hypertension: incidence, survival and mortality. J Clin Epidemiol (1992) 1.62
Effect of murine host genotype on MCF virus expression, latency, and leukemia cell type of leukemias induced by Friend murine leukemia helper virus. Virology (1983) 1.62
Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res (1991) 1.61
Congo red inhibition of scrapie agent replication. J Virol (1993) 1.60
Isolation of functional RNA from plant tissues rich in phenolic compounds. Anal Biochem (1991) 1.59
Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J Virol (1992) 1.59
Role of the host immune response in selection of equine infectious anemia virus variants. J Virol (1987) 1.56
Role and specificity of T-cell subsets in spontaneous recovery from Friend virus-induced leukemia in mice. J Virol (1992) 1.55
Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms. Proc Natl Acad Sci U S A (1997) 1.54
Mechanisms of hypoxemia during panendoscopy. J Clin Gastroenterol (1989) 1.54
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients. J Virol (1998) 1.52
V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J Virol (1999) 1.49
The double life of the prion protein. Curr Biol (1996) 1.48
Purification and ultrastructure of Aleutian disease virus of mink. Nature (1975) 1.47
Effects of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract (2004) 1.45
Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem (2000) 1.44
Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res (2000) 1.44
The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J Virol (1997) 1.43
Different H-2 subregions influence immunization against retrovirus and immunosuppression. Nature (1987) 1.43
Characterization of Ia8 antigen, thy-1.2 antigen, complement receptors, and virus production in a group of murine virus-induced leukemia cell lines. J Immunol (1976) 1.41
Partial unfolding and refolding of scrapie-associated prion protein: evidence for a critical 16-kDa C-terminal domain. Biochemistry (1996) 1.40
Relationship between gestational cocaine use and pregnancy outcome: a meta-analysis. Teratology (1991) 1.40
Bronchial stent placement in a dog with bronchomalacia and left atrial enlargement. J Small Anim Pract (2014) 1.40
M11L: a novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes. J Exp Med (2000) 1.39
Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia. J Immunol (1983) 1.38
Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol (1989) 1.38
Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene. Proc Natl Acad Sci U S A (1979) 1.38
Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J (1997) 1.36